Kate Murray, Lucy Oldfield, Irena Stefanova, Manuel Gentiluomo, Paolo Aretini, Rachel O'Sullivan, William Greenhalf, Salvatore Paiella, Mateus N Aoki, Aldo Pastore, James Birch-Ford, Bhavana Hemantha Rao, Pinar Uysal-Onganer, Caoimhe M Walsh, George B Hanna, Jagriti Narang, Pradakshina Sharma, Daniele Campa, Cosmeri Rizzato, Andrei Turtoi, Elif Arik Sever, Alessio Felici, Ceren Sucularli, Giulia Peduzzi, Elif Öz, Osman Uğur Sezerman, Robert Van der Meer, Nathan Thompson, Eithne Costello
{"title":"Biomarkers, Omics and Artificial Intelligence for Early Detection of Pancreatic Cancer.","authors":"Kate Murray, Lucy Oldfield, Irena Stefanova, Manuel Gentiluomo, Paolo Aretini, Rachel O'Sullivan, William Greenhalf, Salvatore Paiella, Mateus N Aoki, Aldo Pastore, James Birch-Ford, Bhavana Hemantha Rao, Pinar Uysal-Onganer, Caoimhe M Walsh, George B Hanna, Jagriti Narang, Pradakshina Sharma, Daniele Campa, Cosmeri Rizzato, Andrei Turtoi, Elif Arik Sever, Alessio Felici, Ceren Sucularli, Giulia Peduzzi, Elif Öz, Osman Uğur Sezerman, Robert Van der Meer, Nathan Thompson, Eithne Costello","doi":"10.1016/j.semcancer.2025.02.009","DOIUrl":null,"url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.</p>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":" ","pages":""},"PeriodicalIF":12.1000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cancer biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.semcancer.2025.02.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in its late stages when treatment options are limited. Unlike other common cancers, there are no population-wide screening programmes for PDAC. Thus, early disease detection, although urgently needed, remains elusive. Individuals in certain high-risk groups are, however, offered screening or surveillance. Here we explore advances in understanding high-risk groups for PDAC and efforts to implement biomarker-driven detection of PDAC in these groups. We review current approaches to early detection biomarker development and the use of artificial intelligence as applied to electronic health records (EHRs) and social media. Finally, we address the cost-effectiveness of applying biomarker strategies for early detection of PDAC.
期刊介绍:
Seminars in Cancer Biology (YSCBI) is a specialized review journal that focuses on the field of molecular oncology. Its primary objective is to keep scientists up-to-date with the latest developments in this field.
The journal adopts a thematic approach, dedicating each issue to an important topic of interest to cancer biologists. These topics cover a range of research areas, including the underlying genetic and molecular causes of cellular transformation and cancer, as well as the molecular basis of potential therapies.
To ensure the highest quality and expertise, every issue is supervised by a guest editor or editors who are internationally recognized experts in the respective field. Each issue features approximately eight to twelve authoritative invited reviews that cover various aspects of the chosen subject area.
The ultimate goal of each issue of YSCBI is to offer a cohesive, easily comprehensible, and engaging overview of the selected topic. The journal strives to provide scientists with a coordinated and lively examination of the latest developments in the field of molecular oncology.